[14C]-2-Deoxyglucose Autoradiographic Studies of Dopaminergic Drugs in an Animal Model of Parkinson’s Disease
Parkinson’s disease is unique among neurological disorders in that all of its cardinal signs and symptoms can be attributed to brain dopamine deficiency and corrected by dopamine replacement. Although great progress has been made, drug treatment of patients with advanced Parkinson’s disease is severely limited by declining efficacy of dopaminergic drugs, the emergence of drug-induced dyskinesias, and the occurrence of complex clinical fluctuations. Two important questions remain regarding dopaminergic therapy: 1) Which dopamine receptors (i.e. anatomic location, receptor subtype) need to be stimulated to achieve an antiparkinson effect? 2) Subsequent to dopamine receptor stimulation, which neural circuits are activated to mediate these effects? Substantive answers to these questions may suggest new treatment strategies for Parkinson’s disease, or alternatively, more rational use of currently available drugs.
KeywordsDopamine Agonist Superior Colliculus Dopaminergic Drug Midbrain Reticular Formation Dopamine Receptor Stimulation
Unable to display preview. Download preview PDF.
- Harrison, M.B., Wiley, R.G. and Wooten, G.F.: Selective localization of D1 receptors to striatonigral neurons in the rat. Soc. Neuroscí. Abs. 15: 585, 1989.Google Scholar
- Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, M.H., Patlak, C.S., Pettigrew, K.D., Sakurada, 0. and Shinohara, M.: The [14C] deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure and normal values in the conscious and anesthetized albino rat. J. Neurochem. 28: 897–916, 1977.PubMedCrossRefGoogle Scholar
- Ungerstedt, U., Averno, A., Averno, E., Ljungberg, T. and Ranje, C.: Animal models of parkinsonísm. Adv. Neurol. 3: 257–271, 1973.Google Scholar